Please login to the form below

Not currently logged in
Email:
Password:

Horizon adds AZ’s Galbraith to board

UK genomics company also appoints Susan Searle

Horizon Discovery has appointed two new board members, AstraZeneca's head of oncology R&D Susan Galbraith and Susan Searle, ex-CEO of Imperial Innovations Group.

Susan-Galbraith-Horizon

Galbraith is senior VP and head of oncology innovative medicines at AZ and knows Horizon well thanks to a collaboration between the two companies on personalised cancer treatments.

Targeted therapies were a point of note in a recent PMLiVE interview with Galbraith, where she also discussed the rise of immunotherapies and the potential of drug combinations.

Her past experience includes a period as VP of oncology and clinical biomarkers at Bristol-Myers Squibb.

Searle has a more entrepreneurial background, co-founding the technology venture investment business Imperial Innovations Group, where she spent 11 years as its CEO - during which time the company invested £120m in life science companies.

She also sits on the advisory board for the Technology Strategy Board's Emerging Technologies group.

Darrin Disley, CEO of Horizon, said of Galbraith and Searle: “Both have established highly successful careers in their chosen fields and also have proven leadership and advisory success.

“We believe each will be an invaluable asset to Horizon, and look forward to benefitting from their counsel.”

10th June 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....